Sangamo Therapeutics, Inc. Forecast, price target & analysts
Sangamo Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Sangamo Therapeutics, Inc. Classifications & Recommendation:
Sangamo Therapeutics, Inc. Price Target
| Target Price | $5.00 |
| Price | $0.81 |
| Potential |
513.57%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Sangamo Therapeutics, Inc. 2026 .
The average Sangamo Therapeutics, Inc. target price is $5.00.
This is
513.57%
register free of charge
$10.00
1,127.14%
register free of charge
$2.00
145.43%
register free of charge
|
|
| A rating was issued by 7 analysts: 5 Analysts recommend Sangamo Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sangamo Therapeutics, Inc. stock has an average upside potential 2026 of
513.57%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 57.80 | 69.15 |
| 67.20% | 19.64% | |
| EBITDA Margin | -155.31% | 22.70% |
| 197.18% | 114.62% | |
| Net Margin | -180.44% | -84.40% |
| 0.95% | 53.22% |
6 Analysts have issued a sales forecast Sangamo Therapeutics, Inc. 2025 . The average Sangamo Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Sangamo Therapeutics, Inc. EBITDA forecast 2025. The average Sangamo Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Sangamo Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Sangamo Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.49 | -0.27 |
| 66.89% | 44.90% | |
| P/E | negative | |
| EV/Sales | 2.48 |
7 Analysts have issued a Sangamo Therapeutics, Inc. forecast for earnings per share. The average Sangamo Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Sangamo Therapeutics, Inc....
Current Sangamo Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 07 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Mar 18 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 27 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Jan 23 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 02 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Dec 31 2024 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Dec 31 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 07 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Mar 18 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 27 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Jan 23 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 02 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Dec 31 2024 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Dec 31 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
